Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines

Full text
Barbosa, Rebecca S. S. [1] ; Dantonio, Paola M. [1] ; Guimaraes, Tais [1] ; de Oliveira, Mariana B. [1] ; Fook Alves, Veruska L. [1] ; Sandes, Alex Freire [1] ; Fernando, Rodrigo Carlini [1] ; Colleoni, Gisele W. B. [1]
Total Authors: 8
[1] Univ Fed Sao Paulo, Dept Clin & Expt Oncol, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Biochemical and Biophysical Research Communications; v. 519, n. 3, p. 597-604, NOV 12 2019.
Web of Science Citations: 0

Introduction: Multiple myeloma (MM) remains incurable due to high rates of relapse after various treatment regimens. WEE1 is a cell cycle related gene that regulates the G2/M checkpoint and promotes cell cycle suspension for consequent DNA repair. To date, there are clinical studies for the evaluation of WEE1 inhibitors in the treatment of solid tumors and studies on cell lines of non-MM hematological tumors. Objectives: To perform in vitro functional studies to verify the effect of the inhibition of WEE1 on MM cell lines viability and its potential as therapeutic target. Material and methods: WEEI expression was evaluated in 22 newly diagnosed MM patients and in four MM cell lines, RPMI-8226, U266 and SKO-007 and SK-MM2, by quantitative real-time PCR (qPCR). After treatment with the WEEI inhibitor (MK-1775), with or without proteasome inhibitor (bortezomib) pretreatment, we assessed cell viability through Prestoblue functional test, microspheres formation in soft agar, and induction of apoptosis and cell cycle alterations by flow cytometry. Results: All MM cell lines showed WEEI expression by qPCR. RPMI-8226 and U266 showed a 50% reduction in cell viability after 24 h of incubation with MK-1775, at concentrations of 5 mu M and 20 mu M, respectively. SKO-007 showed dose and time dependence to this drug. Combination therapy with bortezomib and MK-1775 abolished the formation of soft agar microspheres in the RPMI-8226 cell line (also responsive to the use of both drugs) and U266, but SKO-007 was resistant to all drugs, isolated and combined. However, treatment of bortezomib followed by MK-1775 (sequential treatment) versus bortezomib alone showed statistically significant impact on cell lines total apoptosis: 88.8% vs 74.1% in RPMI-8222 (confirmed by cell cycle experiments); 92.5% vs 86.6% in U266; and 60.2% 30.9% on SKO-007 (p <0.05). Conclusion: The sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in RPMI-8226, U266, and especially SKO-007 cell lines, more efficiently than the use of the same isolated drugs, highlighting its effect in inhibition of proliferation of tumor cells in MM cell lines. Our data suggest that WEEI can figure as a MM target and that the sequential combination of bortezomib and MK-1775 may be explored in future clinical trials. (C) 2019 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 10/17668-6 - Identification of biomarkers and possible therapeutical targets in B-cell lymphoproliferative disorders
Grantee:Gisele Wally Braga Colleoni
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/21801-2 - Predictors of severity and new treatments for bone marrow neoplasias
Grantee:Sara Teresinha Olalla Saad
Support type: Research Projects - Thematic Grants
FAPESP's process: 15/23983-5 - Isolation and characterization of cancer stem-cells from bone marrow samples of newly diagnosed patients with multiple myeloma
Grantee:Paola Marino Dantonio
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 17/17101-5 - WEE1 gene relevance and its inhibition effect on Myeloma Multiple cancer stem cell survival
Grantee:Taís Guimarães
Support type: Scholarships in Brazil - Scientific Initiation